Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2018; 07(02): 069-071
DOI: 10.4103/sajc.sajc_104_18
Original Article

Role of magnetic resonance imaging in breast cancer management

Selvi Radhakrishna
Department of Surgery, Chennai Breast Center, Chennai, Tamil Nadu
,
S. Agarwal
Department of Medical Oncology, Sir Ganga Ram Hospital, New Delhi
,
Purvish M. Parikh
Department of Oncology, Shalby Cancer and Research Institute, Ahmedabad, Gujarat
,
K. Kaur
Department of Surgical Oncology, Medanta Hospital, Gurgaon, Haryana
,
Shikha Panwar
Department of Radiology, BLK Super Specialty Hospital, New Delhi
,
Shelly Sharma
Department of Radiology, Sir Ganga Ram Hospital, New Delhi
,
Ashish Dey
Department of Surgery, Sir Ganga Ram Hospital, New Delhi
,
K. K. Saxena
Department of Radiology, Sir Ganga Ram Hospital, New Delhi
,
Madhavi Chandra
Department of Radiology, Sir Ganga Ram Hospital, New Delhi
,
Seema Sud
Department of CT Scan and MRI, Sir Ganga Ram Hospital, New Delhi
› Author Affiliations Financial support and sponsorship: Nil.
› Further Information
  PDF Download Permissions and Reprints

Abstract

Magnetic resonance imaging (MRI) of the breast is primarily used as a supplemental tool to breast screening with mammography or ultrasound. A breast MRI is mainly used for women who have been diagnosed with breast cancer, to help measure the size of the cancer, look for other tumors in the breast, and to check for tumors in the opposite breast. For certain women at high risk for breast cancer, a screening MRI is recommended along with a yearly mammogram. MRI is known to give some false positive results which mean more test and/or biopsies for the patient. Thus, although breast MRI is useful for women at high risk, it is rarely recommended as a screening test for women at average risk of breast cancer. Also, breast MRI does not show calcium deposits, known as micro-calcifications which can be a sign of breast cancer.

Key words

Breast imaging - high-risk screening - identify nonresponders - neo-adjuvant setting - X-ray mammogram


Publication History

Article published online:
22 December 2020

© 2018. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Santoro F, Podo F, Sardanelli F. MRI screening of women with hereditary predisposition to breast cancer: Diagnostic performance and survival analysis. Breast Cancer Res Treat 2014;147:685-7.
  • 2 Kuhl C, Weigel S, Schrading S, Arand B, Bieling H, König R, et al. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: The EVA trial. J Clin Oncol 2010;28:1450-7.
  • 3 Kuhl CK, Schrading S, Strobel K, Schild HH, Hilgers RD, Bieling HB, et al. Abbreviated breast magnetic resonance imaging (MRI):First postcontrast subtracted images and maximum-intensity projection-a novel approach to breast cancer screening with MRI. J Clin Oncol 2014;32:2304-10.
  • 4 Houssami N, Turner RM, Morrow M. Meta-analysis of pre-operative magnetic resonance imaging (MRI) and surgical treatment for breast cancer. Breast Cancer Res Treat 2017;165:273-83.
  • 5 Turnbull L, Brown S, Harvey I, Olivier C, Drew P, Napp V, et al. Comparative effectiveness of MRI in breast cancer (COMICE) trial: A randomised controlled trial. Lancet 2010;375:563-71.
  • 6 Peters NH, van Esser S, van den Bosch MA, Storm RK, Plaisier PW, van Dalen T, et al. Preoperative MRI and surgical management in patients with nonpalpable breast cancer: The MONET – Randomised controlled trial. Eur J Cancer 2011;47:879-86.
  • 7 Harness JK, Giuliano AE, Pockaj BA, Downs-Kelly E. Margins: A status report from the annual meeting of the american society of breast surgeons. Ann Surg Oncol 2014;21:3192-7.
  • 8 Martincich L, Montemurro F, De Rosa G, Marra V, Ponzone R, Cirillo S, et al. Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Breast Cancer Res Treat 2004;83:67-76.
  • 9 Rieber A, Brambs HJ, Gabelmann A, Heilmann V, Kreienberg R, Kühn T, et al. Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy. Eur Radiol 2002;12:1711-9.
  • 10 Stucky CC, McLaughlin SA, Dueck AC, Gray RJ, Giurescu ME, Carpenter SG, et al. Does magnetic resonance imaging accurately predict residual disease in breast cancer? Am J Surg 2009;198:547-52.
  • 11 Thibault F, Nos C, Meunier M, El Khoury C, Ollivier L, Sigal-Zafrani B, et al. MRI for surgical planning in patients with breast cancer who undergo preoperative chemotherapy. AJR Am J Roentgenol 2004;183:1159-68.